A Phase 1/2 Study to Evaluate the Safety and Activity of Nivolumab in Combination with Vorolanib, a VEGF tyrosine kinase inhibitor, in Patients with Refractory Thoracic Tumors
JTO Clinical and Research Reports（2023）
关键词
lung cancer,thymic,small cell,anti-angiogenic,immunotherapy,nivolumab,pd-1,refractory
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要